| Identification | Back Directory | [Name]
4(1H)-Quinazolinone, 2-[3-[(2,6-diMethylphenoxy)Methyl]-4-Methoxyphenyl]-2,3-dihydro-3-(3-pyridinylMethyl)- | [CAS]
1338824-20-6 | [Synonyms]
NCGC00229600
2-[3-[(2,6-dimethylphenoxy)methyl]-4-methoxyphenyl]-3-(pyridin-3-ylmethyl)-1,2-dihydroquinazolin-4-one
4(1H)-Quinazolinone, 2-[3-[(2,6-diMethylphenoxy)Methyl]-4-Methoxyphenyl]-2,3-dihydro-3-(3-pyridinylMethyl)- | [Molecular Formula]
C30H29N3O3 | [MDL Number]
MFCD25977097 | [MOL File]
1338824-20-6.mol | [Molecular Weight]
479.57 |
| Hazard Information | Back Directory | [Uses]
NCGC00229600 is an allosteric inverse agonist of thyrotropin receptor (TSHR). NCGC00229600 inhibits both TSH and stimulating antibody activation of TSHRs endogenously expressed in Graves' disease[1]. | [Biological Activity]
NCGC00229600 is an allosteric inverse agonist of thyrotropin receptor (TSHR). NCGC00229600 inhibits both TSH and stimulating antibody activation of TSHRs endogenously expressed in Graves’ disease[1]. | [storage]
Store at -20°C | [References]
[1]. Neumann S, et al. A new small-molecule antagonist inhibits Graves’ disease antibody activation of the TSH receptor. J Clin Endocrinol Metab. 2011 Feb;96(2):548-54. |
|
|